Conveners
Concurrent Session 4: Radiotherapy II
- Jean-François Adam ()
Prof.
Peter Rogers
(University of melbourne)
25/11/2016, 13:30
Radiotherapy
Oral
Microbeam radiotherapy (MRT) was proposed as a novel RT paradigm for treating cancer some time ago. However, progress has been slow and it is unclear when or if human cancers will be treated with synchrotron radiation. There are numerous biological, medical, technical, regulatory and ethical issues to consider before a human is subjected to synchrotron MRT.
This talk will give an overview of...
Mr
Micah Barnes
(RMIT)
25/11/2016, 14:00
Radiotherapy
Oral
Microbeam radiation therapy (MRT), using X-rays from a synchrotron, is a novel, preclinical form of radiotherapy that shows promise of providing a major advance in cancer control if successfully translated to clinical practice (Brauer-Krisch et al, 2010; Crosbie et al, 2010). Clinical translation of MRT requires developing a protocol for a patient positioning system (PPS). Following recent...
Mr
Frank Gagliardi
(William Buckland Radiotherapy Centre)
25/11/2016, 14:15
Radiotherapy
Oral
Dosimetric properties of synchrotron microbeams are extremely difficult to measure due to the small field sizes employed (typically 50 um width with 200 – 400 um peak-to-peak spacing) and must undergo rigorous validation before patient treatments can be performed on the IMBL.
The radiochromic PRESAGE® dosimeter offers a unique opportunity to validate dosimetry models in 3D with similar...
Dr
Duncan Butler
(ARPANSA)
25/11/2016, 14:30
Radiotherapy
Oral
Detectors using diamond for the active layer are becoming more popular in radiotherapy because they have a relatively flat energy response and can be small. Recently published modelling of a new solid-state diamond detector (PTW model 60019) suggests that only a region of diameter 0.6 mm responds to radiation. The manufacturer’s specifications indicate that the active area is a disk of...
Dr
Jayde Livingstone
(Australian Synchrotron)
25/11/2016, 14:45
Radiotherapy
Oral
There are currently two biomedical synchrotron beamlines in the world with an MRT program and an active MRT user base: ID17 at the European Synchrotron Radiation Facility (ESRF), France, and the Australian Synchrotron’s Imaging and Medical Beamline (IMBL). The European program has been ongoing since the 1990s and has identified radioresistant brain tumours as a clinical target for MRT. Indeed,...
Mr
Liam Day
(Royal Melbourne Institute of Technology)
25/11/2016, 15:00
Radiotherapy
Oral
**Introduction**
Synchrotron microbeam radiation therapy (MRT) is a novel radiotherapy modality with significant clinical potential. We have produced a simple dose calculation algorithm for MRT using the Eclipse Treatment Planning System (TPS), by Varian Medical Systems.
**Method**
The calculation engine in Eclipse was configured to directly evaluate ‘peak’ doses. Monte...
